(NASDAQ: ADMA) Adma Biologics's forecast annual revenue growth rate of 16.15% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.29%, and while it is forecast to beat the US market's average forecast revenue growth rate of 13.95%.
Adma Biologics's revenue in 2026 is $509,864,000.On average, 7 Wall Street analysts forecast ADMA's revenue for 2026 to be $132,370,032,991, with the lowest ADMA revenue forecast at $120,359,570,900, and the highest ADMA revenue forecast at $154,534,457,726. On average, 7 Wall Street analysts forecast ADMA's revenue for 2027 to be $157,686,566,650, with the lowest ADMA revenue forecast at $136,268,450,057, and the highest ADMA revenue forecast at $188,727,886,370.
In 2028, ADMA is forecast to generate $185,165,539,741 in revenue, with the lowest revenue forecast at $150,612,863,388 and the highest revenue forecast at $230,219,837,810.